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The aggregation (fibril formation) of amyloid β-protein (Aβ) is considered to be a crucial step in the etiology of Alzheimer's disease (AD). The
inhibition of Aβ aggregation and/or decomposition of fibrils formed in aqueous solution by small compounds have been studied extensively for the
prevention and treatment of AD. However, recent studies suggest that Aβ aggregation also occurs in lipid rafts mediated by a cluster of
monosialoganglioside GM1. This study examined the effects of representative compounds on Aβ aggregation and fibril destabilization in the
presence of GM1-containing raft-like liposomes. Among the compounds tested, nordihydroguaiaretic acid (NDGA), rifampicin (RIF), tannic acid
(TA), and quercetin (QUE) showed strong fibrillization inhibitory activity. NDGA and RIF inhibited the binding of Aβ to GM1 liposomes by
competitively binding to the membranes and/or direct interaction with Aβ in solution, thus at least partly preventing fibrils from forming.
Coincubation of Aβwith NDGA, RIF, and QUE in the presence of GM1 liposomes resulted in elongate particles, whereas the presence of TAyielded
protofibrillar structures. TA and RIF also destabilized fibrils. The most potent NDGA prevented Aβ-induced toxicity in PC12 cells by inhibiting Aβ
accumulation. Furthermore, a comparison of the inhibitory effects of various compounds between aqueous-phase and GM1-mediated aggregation of
Aβ suggested that the two aggregation processes are not identical.
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The aggregation and deposition of amyloid β-protein (Aβ) is
considered to be a crucial step in the etiology of Alzheimer's
disease (AD) [1–3]. A number of studies have been carried out
on the mechanisms of Aβ aggregation and the characterizationAbbreviations: Aβ, amyloid β-protein; AD, Alzheimer's disease; ASP,
acetylsalicylic acid; DMEM, Dulbecco's Modified Eagle's Medium; DMSO,
dimethylsulfoxide; EM, electron microscopy; GM1, monosialoganglioside
GM1; GT1b, trisialoganglioside GT1b; IND, indomethacin; NDGA, nordihy-
droguaiaretic acid; NGF, nerve growth factor; PC, egg yolk L-α-phosphati-
dylcholine; PG, L-α-phosphatidyl-DL-glycerol enzymatically converted from
PC; QUE, quercetin; RIF, rifampicin; RUT, rutin; SM, sphingomyelin; TA,
tannic acid; TC, tetracycline hydrochloride; ThT, thioflovin-T
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doi:10.1016/j.bbamem.2006.09.014of Aβ aggregates in aqueous solutions mimicking biological
fluids [4–9]. Accumulating evidence suggests that the most
neurotoxic species are soluble oligomers acting as intermediates
during the formation of aggregates (fibrils) [10–15]. Therefore,
prevention of Aβ aggregation and/or decomposition of existing
oligomers and fibrils by small compounds are promising
strategies for the prevention and treatment of AD. Various
compounds including β-sheet-binding dyes [16,17], oligopep-
tides [18–24], polyphenols [25–30], antibiotics [27,31,32], and
anti-inflammatory drugs [33–35] have been reported to show
these properties and prevent Aβ neurotoxicity.
On the other hand, membranes are suggested to play an
important role in Aβ aggregation. Yanagisawa et al. discovered
monosialoganglioside GM1-bound Aβ in the brains of patients
with AD and suggested that GM1-bound Aβ may act as a seed
for Aβ polymerization [36,37]. Recently, lipid rafts from the
frontal cortex and the temporal cortex of AD brains were found
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matched control [38]. Gangliosides including GM1 [39–41]
have been shown to accelerate the rate at which soluble Aβ
forms amyloid fibrils in vitro. Our group pointed out that a
cholesterol-dependent cluster of GM1 formed in raft-like
membranes plays a crucial role in the binding of Aβ to mem-
branes [42]. A toxic form of Aβ is generated during the
aggregation with GM1-containing raft-like liposomes, and the
presence of GM1-bound Aβ in AD brains was confirmed by
immunohistochemical and immunoprecipitation studies [43].
These results suggest that the membrane-mediated aggregation
is also a physiologically relevant aggregation process. Recently,
our group found that Aβ fibrils formed with GM1-containing
raft-like liposomes have secondary structures different from
those of fibrils formed in aqueous solution [44]. Therefore, the
screening of compounds that can inhibit the membrane-
mediated Aβ aggregation is an important research subject.
In this study, the effects of representative inhibitors on fibril
formation of Aβ-(1–40) and Aβ-(1–42) in the presence of
GM1-containing raft-like liposomes were examined. The
compounds screened (Fig. 1) include polyphenols (quercetin
QUE, tannic acid TA, nordihydroguaiaretic acid NDGA, and
rutin RUT), antibiotics (rifampicin RIF and tetracycline
hydrochloride TC), and anti-inflammatory drugs (indomethacin
IND and acetylsalicylic acid (aspirin) ASP). NDGA, RIF, TA,
and QUE exhibited potent inhibitory activities. RIF and TA also
effectively degraded preformed fibrils. Furthermore, NDGA
protected PC12 cells from the toxicity of Aβ-(1–42) by
inhibiting the binding of the protein to the cells. Themechanisms
of the inhibitory effects of these compounds will be discussed.2. Materials and methods
2.1. Seed-free Aβ
Human Aβ-(1–40) and Aβ-(1–42) (trifluoroacetic acid salt forms) were
purchased from Peptide Institute (Minoh, Japan). The proteins were dissolved in
0.02% ammonia on ice, and any large aggregates that may act as polymerization
seeds were removed by ultracentrifugation in 500 μL polyallomer tubes at
100,000×g, 4 °C for 3 h [45]. The protein concentration of the supernatant was
determined in triplicate by Micro BCA protein assay (Pierce, Rockford, IL). The
supernatant, which contained essentially monomeric proteins [42,46], was
collected and stored at −80 °C until used. Just before the experiment, the stock
solution was thawed and mixed with an equal volume of double concentrated
buffer (20 mM Tris/300 mM NaCl/2 mM EDTA, pH 7.4).
2.2. Liposomes
GM1, trisialoganglioside GT1b (GT1b), egg yolk L-α-phosphatidylcholine
(PC), L-α-phosphatidyl-DL-glycerol enzymatically converted from PC (PG),
and cholesterol were purchased from Sigma (St. Louis, MO). Bovine brain
sphingomyelin (SM) was obtained from Matreya (Pleasant Gap, PA).
Sonicated liposomes were prepared as follows. GM1, cholesterol, and SM
dissolved in a chloroform–methanol 1:1 (v/v) mixture, chloroform, and
ethanol, respectively were mixed at a molar ratio of 4:3:3 and the solvent was
removed by evaporation in a rotary evaporator. The residual lipid film, after
drying under vacuum overnight, was hydrated with buffer (10 mM Tris/
150 mM NaCl/1 mM EDTA, pH 7.4) and vortex mixed to produce
multilamellar vesicles, which were subsequently sonicated under a nitrogen
atmosphere for 9 min (3 min×3 times) using a probe-type sonicator. Metal
debris from the titanium tip of the probe was removed by centrifugation. Largeunilamellar liposomes were prepared by the extrusion method, as reported
previously [42]. The concentrations of GM1, cholesterol, and phospholipids
were determined at least in triplicate by the resorcinol-hydrochloric acid
method [47], the cholesterol oxidase method (free cholesterol E-test kit by
Wako (Osaka, Japan) [48], and the phosphorus assay [49], respectively. The
actual lipid composition was confirmed to be very close to the expected value
within a 10% error [50]. Therefore, only the GM1 concentration was routinely
determined in the following experiments.
2.3. Fibril formation
Aβ-(1–40) (11 μM) or Aβ-(1–42) (10 μM) was incubated with GM1-
containing liposomes (15 μM GM1) in the absence or presence of various
compounds for 24 h at 37 °C. RUT was purchased from Wako, and the other
compounds were obtained from Nakarai Tesque (Kyoto, Japan). QUE and RIF
were dissolved in dimethylsulfoxide (DMSO). The stock solutions of NDGA,
IM, and ASP were prepared with ethanol. RUT, TA, and TC were soluble in
buffer. The final concentration of the organic solvents was 1 v/v%. Amyloid
formation was estimated by the thioflovin-T (ThT) assay [6,51]. ThT was
obtained from Aldrich (Milwaukee, WI). The sample (final Aβ concentration,
0.5 μM) was added to a 5 μM ThT solution in 50 mM glycine buffer (pH 8.5).
Fluorescence at 490 nmwasmeasured at an excitationwavelength of 446 nmon a
Shimadzu RF-5300 spectrofluorometer with a cuvette holder thermostatted at
25 °C. Among the compounds tested, only RIF showed absorption in this
wavelength region. Therefore, the measured fluorescence intensity was corrected
for inner filter effects (<15%) [52]. Blank values in the absence of Aβ were
subtracted to obtain fluorescence intensities due to Aβ fibrils. A calcein solution
(1 μM) in 10 mM Tris/150 mMNaCl/1 mMEDTA (pH 7.4) buffer was used as a
fluorescence standard.
2.4. Fibril destabilization
Aβ-(1–40) (11 μM) was incubated with GM1-containing liposomes
(15 μM GM1) at 37 °C, while amyloid formation was monitored using the
ThT assay. After 9 h, various compounds dissolved in DMSO were added at a
final concentration of 150 μM (1 v/v% DMSO), and the monitoring of
amyloid formation was continued. The same volume of DMSO was added as a
control.
2.5. Electron microscopy (EM)
Reaction mixtures were spread on carbon-coated grids, negatively stained
with 1% phosphotungstic acid, pH 7.0, and examined under a Hitachi H-7000
electron microscope with an acceleration voltage of 75 kV.
2.6. Binding of Aβ to liposomes
Aβ-(1–40) (11 μM) was incubated with GM1-containing liposomes (15 μM
GM1) in the presence or absence of various compounds (150 μM) for 10 min at
37 °C. The mixtures were ultracentrifuged at 650,000×g for 30 min. The free
concentration of Aβ in the supernatant was determinedwith the BetaAmyloid 1–
40 Biotrak ELISA System (Amersham Biosciences, Piscataway, NJ). The bound
concentration was calculated by subtracting the free concentration from the total
concentration.
2.7. Binding of inhibitors to liposomes
NDGA and RIF (150 μM) were incubated with GM1-containing liposomes
(150 μM GM1) in the presence or absence of Aβ-(1–40) (11 μM) for 10 min at
37 °C. The mixtures were ultracentrifuged at 650,000×g for 30 min. For GT1b/
cholesterol/SM (4:3:3), GM1/cholesterol/SM (4:3:3), SM/cholesterol (2:1), PG/
PC (4:6), PC/cholesterol (2:1), or PC (500 μM) liposomes, large unilamellar
vesicles and a longer ultracentrifugation time of 3 h were used, because sonicated
vesicles of these lipids could not be sedimented. The free concentration of NDGA
and RIF in the supernatant was determined by measuring optical density at 281
and 471 nm, respectively. The bound concentrationwas calculated by subtracting
the free concentration from the total concentration.
Fig. 1. Chemical structures of the compounds used in this study.
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Dulbecco's Modified Eagle's Medium (DMEM), horse serum, bovine
serum, penicillin, and streptomycin were purchased from Invitrogen (Carlsbad,CA). Rat pheochromocytoma PC12 cells were cultured in DMEM containing
5% horse serum, 10% bovine serum, 100 units/ml penicillin, and 0.1 mg/ml
streptomycin at 37 °C with 5% CO2. After being plated at a density of
100,000 cells onto a poly-D-lysine-coated 35-mm glass bottom dish, cells were
Fig. 2. Effects of various compounds on Aβ fibril formation. (A) Aβ-(1–40)
(11 μM) or (B) Aβ-(1–42) (10 μM) was incubated in buffer (10 mM Tris/
150 mMNaCl/1 mMEDTA, pH 7.4) with various compounds (150 μM) for 24 h
at 37 °C in the presence of GM1/cholesterol/SM (4:3:3) liposomes (15 μM as
GM1) (filled bars) or 0.3 μM fibrils preformed in buffer (open bars) as a seed,
respectively. Fibril formation was estimated by ThT assay, and the fluorescence
intensity in the absence of any compounds was set to 100% (n=5).
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nerve growth factor (NGF; Alomone, Jerusalem, Israel) in serum-free DMEM
for 6–7 days.
2.9. Congo red staining
NGF-differentiated PC12 cells were incubated with 10 μM Aβ-(1–42)
(Peptide Institute) with or without 10 μM NDGA in serum-free DMEM
containing 50 ng/ml NGF for 24 h at 37 °C with 5% CO2, and then rinsed twice
with Tris-buffered saline (TBS, 150 mM NaCl and 10 mM Tris, pH 7.4).
Accumulated Aβ amyloids on the cell membranes were stained with 20 μM
Congo red (Nacalai Tesque, Kyoto, Japan) in TBS for 30 min at room
temperature [53], and then rinsed twice with TBS. These cells were visualized
using the 63× C-Apochromat objective of a Zeiss LSM 510 confocal laser
scanning microscope.
2.10. Live/dead assay
NGF-differentiated PC12 cells were incubated with 10 μM Aβ-(1–42)
with or without 10 μM NDGA, RIF, or TA in serum-free DMEM containing
50 ng/ml NGF for 24 h at 37 °C with 5% CO2, and then rinsed twice with
TBS. Cells were stained with 0.4 μM calcein AM and 0.4 μM EthiD-1
(Molecular Probes, Eugene, OR) in TBS for 30 min at room temperature, and
then rinsed twice with TBS. The cells were visualized using the 20× Plan
Apochromat objective. Calcein AM- and EthD-1-positive cells represented
live and dead cells respectively.
3. Results
3.1. GM1-mediated versus aqueous-phase aggregation
The effects of various compounds on Aβ amyloid formation
in the presence and absence of GM1-containing liposomes were
compared. Aβ-(1–40) showed maximal ThT fluorescence
intensity after a 24 h incubation at 37 °C in the presence of
liposomes, whereas no ThT fluorescence was observed in its
absence (data not shown), indicating GM1-bound Aβ acts as a
seed for Aβ fibril formation, as reported previously [41]. The
compounds screened exhibited inhibitory activities in the rank
order NDGA>RIF>QUE≈TA>TC≥ IND>RUT≈ASP (no
effect) at a compound-to-protein ratio of 14 (Fig. 2A, filled
bars). The effects of more potent compounds (NDGA, RIF, TA
and QUE) on the aggregation of more fibrillogenic and toxic
Aβ-(1–42) were also examined. These compounds also
inhibited the increase in ThT fluorescence in the presence of
GM1-containing liposomes (Fig. 2B). NDGA was again most
potent. The inhibitory effects of these compounds on fibril
formation were confirmed by EM. In the absence of any
inhibitors, Aβ-(1–40) formed typical nonbranched fibrils (Fig.
3A). The presence of the most effective agent NDGA almost
completely inhibited fibril formation, in accordance with the
ThT assay. Small elongate particles were observed with no
fibrillar structure (Fig. 3B). RIF and QUE exhibited similar
effects (data not shown). The concentration dependence of each
potent inhibitor is shown in Fig. 4. The 50% inhibitory
compound-to-Aβ ratios were ≤0.8, ≤0.9, 1.3, and 5.5 for
NDGA, TA, RIF, and QUE, respectively. TA showed a strange
profile. ThT fluorescence was reduced to 20% of the control
value at a ratio as low as 1.4, whereas no additional effect was
observed at higher ratios. EM results showed the formation of
protofibril-like structures (Fig. 3C).The effects of the compounds on Aβ-(1–40) fibril formation
in aqueous phase were also examined. A trace amount of
preformed fibrils was added to facilitate fibril formation [41].
The rank order of the inhibitory effect was NDGA>TA>R-
IF>TC≈QUE>IND≈RUT>ASP (Fig. 2A, open bars), in
general agreement with previous studies: NDGA and TA
possess stronger activities than RIF, TC, and QUE [27,28]. RIF
was more potent for GM1-mediated aggregation, whereas RUT,
TA and TC were more effective for fibril formation in buffer.
3.2. Effects of compounds on binding of Aβ to liposomes
To obtain insights into the mechanism of prevention of
GM1-mediated fibrillization, we determined the effects of
NDGA, RIF, QUE, and TA on the binding of Aβ-(1–40) to
GM1-containing liposomes. In the absence of any inhibitors,
about 60% of Aβ was bound to the liposomes under the
conditions examined (Fig. 5). The presence of NDGA and RIF
significantly reduced the binding to the membranes. In contrast,
QUE and TA did not affect the binding.
3.3. Binding of inhibitors to liposomes
The above results suggest that NDGA and RIF may bind to
GM1-liposomes, covering the binding sites for Aβ. Therefore,
the binding of these compounds to the liposomes was
Fig. 5. Inhibition of Aβ binding to GM1 liposomes by various compounds.
Aβ-(1–40) (11 μM) was incubated in buffer (10 mM Tris/150 mM NaCl/1 mM
EDTA, pH 7.4) with various compounds (150 μM) for 10 min at 37 °C in the
presence of GM1-containing liposomes (150 μM as GM1). After ultracen-
trifugation of the mixtures, the free concentration of Aβ in the supernatant was
determined by ELISA (n=6).
Fig. 3. Negative stain transmission EM. Aβ-(1–40) (11 μM) was incubated in
buffer (10 mM Tris/150 mM NaCl/1 mM EDTA, pH 7.4) with various
compounds (150 μM) for 18 h at 37 °C in the presence of GM1-containing
liposomes (15 μM as GM1). (A) No compound (control). (B) With NDGA.
(C) With TA. The fibril destabilization by TA is shown in D. Aβwas incubated in
the buffer with the GM1-containing liposomes for 18 h at 37 °C. TA was
subsequently added, and the incubation was continued for an additional 24 h.
Liposomes (20–50 nm) are seen in all micrograms. Bars represent 200 nm.
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of RIF were bound to the membranes, respectively. The
coexistence of Aβ-(1–40) competitively inhibited the binding
of these compounds.
To get insights into the mechanism of membrane binding of
these compounds, the binding to liposomes of various lipid
compositions was investigated (Fig. 6B). NDGA (filled bars)
bound to zwitterionic PCmore strongly than to GM1-liposomes,
whereas RIF (open bars) showed little affinity for PC, SM/
cholesterol and negatively charged PG/PC bilayers. The weak
affinity for these membranes was not due to larger liposomeFig. 4. The concentration dependence of fibrillation inhibitory effects. Fibril
formation experiments were performed as in Fig. 2A at different compound-to-
protein ratios in the presence of GM1 liposomes (n=5). The Aβ-(1–40)
concentration was kept at 11 μM. Compounds: ○, QUE; □, RIF; ▵, TA; ▿,
NDGA.sizes. RIF was incubated with smaller sonicated vesicles, and
the mixtures were separated by gel filtration. RIF was not
detected in the vesicle fractions (data not shown). In contrast,
RIF also tightly bound to GT1b-containing raft-like mem-
branes (Fig. 6B).Fig. 6. Competitive binding of Aβ and compounds to GM1 liposomes. (A)
NDGA or RIF (150 μM) was incubated in buffer (10 mM Tris/150 mM NaCl/
1 mM EDTA, pH 7.4) with GM1-containing liposomes (150 μM as GM1) for
10 min at 37 °C in the presence (filled bars) or absence (open bars) of 11 μM
Aβ-(1–40). After ultracentrifugation of the mixtures, the free concentration of
each compound in the supernatant was determined by optical density (n=2 for
NDGA and n=4 for RIF). (B) NDGA (filled bars) or RIF (open bars) (150 μM)
was incubated in the buffer with 375 μM GT1b/cholesterol/SM (4:3:3), GM1/
cholesterol/SM (4:3:3), SM/cholesterol (2:1), PG/PC (4:6), PC/cholesterol (2:1),
or PC (500 μM) liposomes for 10 min at 37 °C. The binding of the compounds to
the liposomes was determined as (A). N. D.: not determined.
Fig. 8. Cytotoxicity. Inhibitors (10 μM) were incubated with NGF-differentiated
PC12 cells in the absence or presence of 10 μM Aβ-(1–42) for 24 h at 37 °C.
(A) Cytotoxicity was determined by the live/dead assay (n=3). (B) A DIC
image in the presence of TA only without the protein.
127K. Matsuzaki et al. / Biochimica et Biophysica Acta 1768 (2007) 122–1303.4. Fibril destabilization
If these compounds also possess the ability to destabilize
existing fibrils, it would be beneficial for therapeutic
purposes. Aβ was incubated with GM1-liposomes, while
ThT fluorescence was monitored (Fig. 7). After a 7 h lag, the
fluorescence intensity abruptly increased, reaching a maximal
value within 3 h. The addition of compounds at 9 h, where
the ThT value reached 40% of the maximal value, reduced
the fluorescence, indicating the possibility that these com-
pounds destabilize fibrils. The rank order of effectiveness was
NDGA>TA>RIF>QUE. After a 24 h coincubation, the
mixtures were examined by EM. The RIF-treated sample
contained elongate particules similar to Fig. 3B (data not
shown). The addition of TA yielded short sheared fibrils and
small aggregates (Fig. 3D). Despite almost the nullification of
ThT fluorescence, the NDGA-treated specimen contained a lot
of fibrils similar to those in Fig. 3A (data not shown).
3.5. Cell study
The protective effects of the potent inhibitors NDGA, TA
and RIF on Aβ-induced cytotoxicity were examined by use of
NGF-differentiated PC12 cells as a neuronal model. More toxic
Aβ-(1–42) was used for this purpose instead of Aβ-(1–40).
Aβ-(1–42) (10 μM) was incubated with cells in the absence or
presence of 10 μM inhibitors for 24 h at 37 °C. The cell viability
was determined by the live/dead assay (Fig. 8A). The most
potent inhibitor, NDGA, significantly prevented Aβ-induced
cytotoxicity, whereas RIF had no inhibitory effect. The
incubation with TA alone without Aβ changed the cell
morphology (Fig. 8B), indicating cytotoxicity, which was not
reflected by cell viability (data not shown).
To confirm that NDGA protected cells from Aβ by blocking
the binding of the protein to the cells, the cellular accumulation
of Aβ-(1–42) was visualized with the amyloid-specific dye
Congo red [53]. We have recently shown that this dye can beFig. 7. Fibril destabilization by various compounds. Aβ-(1–40) (11 μM) was
incubated in buffer (10 mM Tris/150 mM NaCl/1 mM EDTA, pH 7.4) with
GM1-containing liposomes (15 μM GM1) at 37 °C, while amyloid formation
was monitored with the ThT assay. After 9 h, various compounds dissolved in
DMSO were added at a final concentration of 150 μM (1 v/v% DMSO), and
amyloid formation was continued to be monitored (n=5). The same volume of
DMSO was added as a control. Compounds: ⋄, none (control); ○, QUE; □,
RIF; ▵, TA; ▿, NDGA.utilized to stain amyloids of native Aβ-(1–42) formed on living
cell membranes (Wakabayashi, M. and Matsuzaki, K., unpub-
lished work). In the absence of NDGA, cells were stained by the
dye (Fig. 9A), suggesting Aβ accumulated and formedFig. 9. Inhibition of Aβ accumulation in PC12 cells by NDGA. Aβ-(1–42)
(10 μM) was incubated with NGF-differentiated PC12 cells in the absence
(A and B) or presence (C and D) of 10 μM NDGA for 24 h at 37 °C. Amyloids
were stained by Congo red (A and C). B and D show DIC images. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 10. Mechanisms of the inhibition of Aβ fibrillation by various compounds
in lipid rafts. Aβ binds to a GM1 cluster, forming a β-sheet structure that acts
as a seed for fibrillation. NDGA and RIF block the binding process by
competitively binding to the membrane and/or direct interaction with Aβ in
solution. These compounds as well as QUE inhibit the subsequent fibrillation
process by forming elongate particles. The presence of TA leads to the
formation of protofibrils.
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almost completely inhibited amyloid formation (Fig. 9C).
4. Discussion
4.1. GM1-mediated versus aqueous-phase aggregation
This study examined for the first time the effects of various
compounds on Aβ fibril formation mediated by GM1. The
present data suggest that Aβ fibrils formed in GM1-containing
membranes are not identical to fibrils formed in aqueous
solution, in accordance with our previous infrared spectroscopic
study [44]. The order of fibrillization inhibitory effects of
various compounds was different in both cases (Fig. 2A).
Notably, TA, which is known to be one of the most potent
inhibitors of aqueous-phase fibril formation of Aβ [27], was less
effective for membrane-phase aggregation. In solution, the
addition of an equimolar amount of TA completely inhibited the
ThT fluorescence increase, and EM showed that TA destabilizes
seeds of fibrillar Aβ [27]. In contrast, the maximal inhibition of
ThT fluorescence development by TA was ∼80% in the
presence of GM1 liposomes (Fig. 4), and protofibrillar structures
were generated (Fig. 3C). ThT molecules bound to the structures
appear to be weakly fluorescent. In supporting this interpreta-
tion, we observed that fluorescence intensity of ThT bound to
protofibrils of Aβ-(1–40) formed in solution was also 4-fold
weaker than that bound to mature fibrils (Naiki et al., un-
published observation).
The fibril destabilization study also supports the above
conclusion. The addition of NDGA hardly affected the
morphology of fibrils preformed in membranes as examined
by EM (data not shown), whereas this compound breaks down
fibrils formed in solution into amorphous aggregates [26].
Strangely, the addition of NDGA almost nullified ThT fluo-
rescence (Fig. 7), suggesting that NDGA possesses a higher
affinity for fibrils formed in membranes than ThT. In contrast,
RIF destabilized preformed fibrils into elongate particles even
in the presence of fibrils (data not shown), probably because
binding of the more bulky structure (Fig. 1) is advantageous for
breaking down preformed fibrils.
Aβ fibrillization in solution proceeds in the nucleation-
dependent polymerization model characterized by the presence
of a lag phase [6,7]. Hayashi et al. reported that the lag phase
disappeared in the presence of GM1-containing liposomes
(500 μM as GM1, [Aβ]=50 μM), concluding that GM1-bound
Aβ serves as a seed [43]. However, the present results (Fig. 7)
indicate that the situation is more complicated. The reduction of
liposome concentration resulted in the appearance of a lag
phase, suggesting that the membrane binding and subsequent
conformational change, which is a fast process, is not enough
for the seed formation.
4.2. Mechanism of inhibition of fibrillization in GM1 liposomes
The four more potent inhibitors can be classified into several
groups (Fig. 10). NDGA and RIF inhibit fibril formation by two
different mechanisms, which makes these compounds signifi-cantly active (Fig. 4). First, these compounds prevent the
binding of Aβ to GM1 liposomes by competitively binding to
the membranes (Figs. 5 and 6). NDGA also showed a high
affinity for PC liposomes (Fig. 6B), suggesting that the driving
force behind the membrane binding of NDGA is hydrophobic
interaction. Since Aβ has the hydrophobic C-terminal part as
well as several aromatic amino acid residues, NDGA may also
directly interact with Aβ in solution, preventing the binding of
the protein to membranes. Indeed, preliminary NMR measure-
ments suggested this possibility, although the direct interaction
will be diminished at lower Aβ concentrations at which
liposome and cell studies were performed (unpublished work).
Interestingly, QUEwith a structure similar to NDGA, in that two
phenol rings are separated by several carbon atoms, loses
membrane affinity. The presence of additional oxygen atoms
makes the molecule more polar than NDGA, preventing
membrane binding. The weak toxicity of NDGA itself
(Fig. 8A) may be related to the ‘non-specific binding’ of the
compound to membranes. In contrast, RIF specifically binds to
ganglioside-containing membranes (Fig. 6B). The compound
showed marginal affinity for zwitterionic PC, negatively
charged PG/PC, and raft-like SM/cholesterol bilayers. The
presence of multiple OH groups (Fig. 1) may be advantageous
for the specific interaction with gangliosides, which also possess
a number of OH groups. The second mechanism for the
inhibition of fibril formation involves the formation of elongate
particles (Fig. 3B).
On the other hand, QUE and TA block Aβ aggregation
without affecting the membrane binding of the protein (Fig. 5).
QUE forms elongate particles with Aβ similarly to NDGA and
RIF, whereas TA induces protofibrillar structures (Fig. 3C). The
formation of elongate particles may be indicative of specific
interaction between the compounds and a conformationally al-
tered form (probably β-sheet) of Aβ either formed during the
aggregation process or in the fibrils. Krebs et al. recently
proposed that Th-T binds to channel-like crevices that run along
the length of β-sheets [54]. Relatively compact planar structures
may be important for the formation of elongate particles (Fig. 1).
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We have recently confirmed that Aβ binds to and accu-
mulates on GM1-rich domains on cell membranes, guaranteeing
the relevance of our liposomal model system [55]. Equimolar
NDGA almost completely inhibited Aβ-induced cytotoxicity
(Fig. 8). Although oxidative stress has been suggested to be
involved in Aβ-induced cytotoxicity [56–58], the cytoprotec-
tive effect of NDGA is not due to the antioxidant activity of the
compound but due to the inhibition of the fibril formation of Aβ
on cells (Fig. 9), in accordance with the liposomal study.
Polyphenols, such as (−)-epigallocatechin gallate [59] and
curcumin [30], are reported to cross the blood–brain barrier.
Taking the small molecular size into consideration, NDGA
appears to be a promising leading compound as a preventive
drug for AD.
In contrast to NDGA, RIF and TA were disappointing drug
candidates. Equimolar RIF had no effect on Aβ-induced
cytotoxicity (Fig. 8). Tomiyama et al. reported that RIF comple-
tely protected NGF-differentiated PC12 cells from cytotoxicity
triggered by Aβ-(1–40) preaggregated in solution [31].
However, they used a 50-fold excess of the compound. TA
itself showed cytotoxicity (Fig. 8B), although it is reported to be
nontoxic at a dietary concentration of up to 5% [60].
In summary, NDGA, RIF, and TA are potent inhibitors of
both the solution-phase and membrane-mediated formation of
Aβ fibrils in vitro, although the individual inhibitory mechan-
isms are different. Although TA and RIF possess effective
destabilizing activities for fibrils formed in membranes, our cell
study showed that NDGA is a promising candidate as a lead
compound for AD therapy.
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